2 terminated, 1 active not recruiting, 1 completed. 3 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 2 | 2 | Terminated 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Sonnet BioTherapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer SON-1010 - Advanced Solid Tumor, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Sonnet BioTherapeutics | 40 | 2023-09-15 | 2026-02-03 |
| SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) SON-080 - Chemotherapy-induced Peripheral Neuropathy (CIPN) | Phase 1 / Phase 2 | Terminated | Sonnet BioTherapeutics | 9 | 2022-10-27 | 2024-04-12 |
| Study of SON-1010 (IL12-FHAB) in Healthy Adults SON-1010 (IL12-FHAB) - Healthy Adult | Early Phase 1 | Completed | Sonnet BioTherapeutics | 32 | 2022-07-27 | 2023-09-06 |
| Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors SON-1010 - Advanced Solid Tumor, Soft Tissue Sarcoma Adult | Phase 1 | Active not recruiting | Sonnet BioTherapeutics | 42 | 2022-04-20 | 2026-02-03 |
Australia (3) · United States (2)
Richard Kenney, MD (3) · Richard T Kenney, MD (1)